Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Shareholder Meeting (November 2022)

13 slides from Neuroscientific Biopharmaceuticals's shareholder meeting presentation, Nov 24, 2022

  1. Slide 1: Chairman's 2022 Annual General Meeting Address

    ASX ANNOUNCEMENT 24 NOVEMBER 2022 Chairman’s 2022 Annual General Meeting Address For personal use only Good afternoon ladies and gentlemen. Welcome to the 2022 AGM for NeuroScientific Biopharmaceuticals Limited. My name is Paul Rennie, the Chairman & Interim CEO of NeuroScientific. I will also Chair

  2. Slide 2: About NeuroScientific Biopharmaceuticals Ltd

    About NeuroScientific Biopharmaceuticals Ltd NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinBTM, a ther

  3. Slide 3: Novel Drug Therapies for Neurodegenerative Conditions - AGM Presentation

    For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS AGM PRESENTATION NOVEMBER 2022 • ASX: NSB neuroscientific.com

  4. Slide 4: Disclaimer

    DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  5. Slide 5: Q&A Functionality

    Q&A FUNCTIONALITY For personal use only 3. Hit enter on your 1. Click on the Q&A icon 2. Type your question in keyboard to submit your the new Q&A window message To contact Automic support: 1300 816 159 neuroscientific.com • 3

  6. Slide 6: NeuroScientific Biopharmaceuticals Ltd - Capital Structure

    NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD For personal use only CAPITAL STRUCTURE DEVELOPING NOVEL THERAPEUTICS FOR NEURODEGENERATIVE CONDITIONS NSB 143.5m 16.8m ASX Code Shares on Unlisted EMTINB™: LEAD DRUG CANDIDATE issue options  Peptide-based therapeutic with novel MOA for treating neurodegenerat

  7. Slide 7: Leadership & Management

    LEADERSHIP & MANAGEMENT For personal use only BOARD & MANAGEMENT Paul Rennie Stephen Quantrill Dr Anton Uvarov Executive Non-Executive Director Non-Executive Director Chairman & Interim • 20+ years corporate advisory • Founding Director of • Managing Director of McRae CEO Investments Actinogen (ASX:

  8. Slide 8: HREC Submission Refused on Three Matters

    HREC SUBMISSION REFUSED ON THREE MATTERS For personal use only NSB understands the HREC decision, and we understand their position. The HREC explained the three reasons for the refusal were safety, purity of EmtinBTM and efficacy. • Safety- local injection site tolerability was not satisfactorily de

  9. Slide 9: NSB Next Steps for EmtinB (3-6 months)

    NSB NEXT STEPS FOR EMTINBTM (3-6 months) For personal use only • Safety: Two independent toxicologists (one US board certified and one with both US and EU board certification) to perform a thorough GAP analysis. Following completion of all required toxicology, a formal independent toxicology report

  10. Slide 10: NSB Next Steps (3-6 months)

    NSB NEXT STEPS (3-6 months) For personal use only • Interim CEO: Paul Rennie appointed interim CEO to oversee the next 3-6 months whilst the company works to identify a permanent CEO. • Independent review: The Company has engaged an independent team to conduct a full review of what occurred in the l

  11. Slide 11: Pivotal Milestones: Key Milestones Completed

    PIVOTAL MILESTONES For personal use only KEY MILESTONES COMPLETED  SAFETY & TOXICITY STUDIES IN ANIMALS (NEUROLOGY INDICATIONS)  PRECLINICAL BIOMARKER PROGRAM – IDENTIFIED POTENTIAL PD & EFFICACY BIOMARKERS  MANUFACTURING OF CLINICAL-GRADE (GMP) EMTINB™  HREC APPROVAL TO COMMENCE EARLY-PHASE CLI

  12. Slide 12: Pivotal Milestones: Near-Term Key Milestones

    PIVOTAL MILESTONES For personal use only NEAR-TERM KEY MILESTONES  PIVOTAL EFFICACY RESULTS FROM PRECLINICAL MULTIPLE SCLEROSIS MODEL  COMPLETION OF EARLY-PHASE CLINICAL TRIAL  HREC NEW SUBMISSION TO COMMENCE PHASE I CLINICAL TRIAL  RECRUITMENT OF FIRST COHORT FOR PHASE I CLINICAL TRIAL  FIRST

  13. Slide 13: For more information contact

    For personal use only neuroscientific.com For more information contact: Abby Macnish – CFO and Company Secretary E: Abby Macnish [email protected] Paul Rennie- Chairman & Interim CEO E: [email protected]

NeuroScientific Biopharmaceuticals — Shareholder Meeting (November 2022) on 6ix